Portfolio Design Labs LLC Invests $457,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Portfolio Design Labs LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 520 shares of the biopharmaceutical company’s stock, valued at approximately $457,000.

Several other institutional investors have also made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. MCF Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the last quarter. Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. lifted its stake in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $9.58 on Wednesday, hitting $963.58. The stock had a trading volume of 65,467 shares, compared to its average volume of 472,530. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The firm’s 50 day moving average price is $945.50 and its 200-day moving average price is $918.05. The company has a market capitalization of $106.18 billion, a price-to-earnings ratio of 28.75, a price-to-earnings-growth ratio of 2.03 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.34 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on REGN shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $989.36.

View Our Latest Report on REGN

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares in the company, valued at approximately $12,994,492.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now directly owns 13,431 shares in the company, valued at approximately $12,994,492.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now owns 18,282 shares in the company, valued at $17,953,838.10. The disclosure for this sale can be found here. Insiders have sold a total of 54,071 shares of company stock worth $52,812,907 in the last 90 days. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.